New report supports use of caldolor® as a standard of care across patient populations

Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants nashville, tenn. , april 2, 2024 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, today announced the release of a special report evaluating the growing amount of current data supporting the use of its caldolor® product (intravenous ibuprofen, or ivib) as a standard of care for the treatment of pain and fever in adults, children and infants.
CPIX Ratings Summary
CPIX Quant Ranking